Diabetic kidney disease: act now or pay later

In 2003, the International Society of Nephrology and the International Diabetes Federation launched a booklet called ‘Diabetes and Kidney Disease: Time to act’ to highlight the global pandemic of type 2 diabetes and diabetic kidney disease. It aimed to alert governments, health organizations, providers, doctors and patients to the increasing health and socio-economic problems due to diabetic kidney disease and its sequelae, end stage kidney disease requiring dialysis and cardiovascular death. Seven years later, the same message has become even more urgent. World Kidney Day 2010, under the auspices of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations IFKF), together with the International Diabetes Federation (IDF), provides yet another chance to underline the importance of diabetic kidney disease, stress its lack of awareness at both public and government levels and emphasize that its management involves prevention, recognition and treatment of its complications. Primary prevention of type 2 diabetes will require massive lifestyle changes in the developing and developed world supported by strong governmental commitment to promote lifestyle and societal change.

[1]  M. Woodward,et al.  Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes , 2009, Diabetes Care.

[2]  Mark Woodward,et al.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[3]  G. Bakris,et al.  Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  G. Bakris,et al.  Novel therapies of diabetic nephropathy , 2009, Current opinion in nephrology and hypertension.

[5]  S. Schinner Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[6]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[7]  R. Bilous,et al.  Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[8]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[9]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[10]  J. Shaw,et al.  Limited knowledge of kidney disease in a survey of AusDiab study participants , 2008, The Medical journal of Australia.

[11]  Merlin C. Thomas,et al.  Screening for chronic kidney disease in patients with diabetes: are we missing the point? , 2008, Nature Clinical Practice Nephrology.

[12]  K. Iseki,et al.  Chronic kidney disease perspectives in Japan and the importance of urinalysis screening , 2008, Clinical and Experimental Nephrology.

[13]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[14]  Ho-Young Son,et al.  Epidemic obesity and type 2 diabetes in Asia , 2006, The Lancet.

[15]  H. Parving,et al.  Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. , 2006, Kidney international.

[16]  M. Mauer,et al.  Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.

[17]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[18]  Robert Atkins,et al.  The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. , 2002, Diabetes care.

[19]  Michael J Lysaght,et al.  Maintenance dialysis population dynamics: current trends and long-term implications. , 2002, Journal of the American Society of Nephrology : JASN.

[20]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[21]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[22]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[23]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.